The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Novo Nordisk's weight-loss pill reached 3 million prescriptions in the U.S. since its market launch. Subsequently, the company identified an IT security incident involving unauthorized access to a limited number of internal IT systems. These developments occur as the company continues its operational activities across different markets.